To possibly detect cells bearing markers of myeloid and plasmacytic cells, FACS analysis was performed. A major part of BM cells expressed myeloid markers (CD33: 75%; CD13: 63%; CD117: 9%), while 3% of the cells were positive for plasma cell antigens (CD38, CD138). Within the CD138 + population 6% coexpressed CD117 and CD13, and 4% coexpressed CD117 and CD33. These populations, however, were too small to identify bcr-abl-positive cells. The attempt to expand a potential BM progenitor of CML and MM cells resulted in five cell lines, which appeared morphologically as immature myeloma cells (large size, perinuclear clear zone, Russel bodies and giant multinucleated cells), and express the following surface markers: CD38 (88%), CD19 (89%), CD10 (67%), CD33 (16%), CD13 (8%) according to FACS analysis. A small fraction of these cells (o1%) was found to coexpress surface markers of myeloid progenitors (CD13, CD33, CD117) and markers characteristic for plasma cells (CD38, CD138). FISH analysis, however, did not provide evidence for a bcr-abl fusion signal and chromosome 13q14 was found to be diploid.
TO THE EDITOR
The importance of angiogenesis for growth and viability of solid tumors has been established. Knowledge on these relations in hematological tumors, however, is circumstantial. Tumor microvessel density predicts a risk of progression in multiple myeloma, 1 is correlated with progression stages in both B-cell non-Hodgkin's lymphomas 2 and matches in step with the growth of acute leukemias and myelodysplastic syndromes.
Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (B-cell CLL). 3 The two most potent angiogenesis inducers, namely vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are both involved in B-cell CLL. VEGF, present in both the patients' serum and leukemic cells is related to poor prognosis, while FGF-2 expression by leukemic cells is associated with advanced disease and resistance to fludarabine.
Tumor cells are surrounded by an infiltrate of inflammatory cells, namely lymphocytes, neutrophils, macrophages and mast cells (MC), which communicate via a complex network of intercellular signaling pathways mediated by surface adhesion molecules, cytokines and their receptors. MC density is highly correlated with the extent of both normal and pathological angiogenesis, such as that in chronic inflammatory diseases and tumors. various products released by MC, including VEGF, FGF-2 and tryptase. 4 We have previously demonstrated in three hematological malignancies, namely multiple myeloma, B-cell non-Hodgkin's lymphoma and myelodysplastic syndromes, that there is a striking association between MC and microvessel counts and that both increase in function of tumor progression, as defined by its increasing malignancies grades. [5] [6] [7] Morever, in B-cell non-Hodgkin's lymphoma and myelodysplastic syndromes angiogenesis is highly correlated with the total and MC tryptase-positive counts. 7, 8 Tryptase in MC secretory granules, in fact, is angiogenic both in vitro and in vivo experimental models, and specific tryptase inhibitors suppress this activity.
Here, we demonstrated a correlation between the extent of angiogenesis and the number of tryptase-reactive MC in B-cell CLL on tissue sections selected from 33 Binet stage A B-cell CLL patients as compared to the controls (10 patients with anemia because of iron or vitamin B 12 deficiences). There were significant differences in the microvessels counts (w 2 ¼ 32.5, d.f. ¼ 3, Po0.001; F ¼ 35.6, Po0.001) and the tryptase-positive MC counts varied significantly (w 2 ¼ 34.4, d.f. ¼ 3, Po0.001; F ¼ 39.7, Po0.001). Figure 1 shows the differences in both microvessel (panels a, b) and tryptase-positive MC (panels c, d) density between the control (panels a, c) and the pathological (panels b, d) groups. MC were generally scattered throughout the neoplastic tissue and within the interstitial stroma, where they rested near or around the blood capillaries.
High vascularity in bone marrow of patients with B-cell CLL has been related to high levels of angiogenic cytokines, such as VEGF and FGF-2. VEGF has been measured in both serum and leukemic cells;
3 VEGF released by CLL stimulates endothelial proliferation in vitro and conditioned media from cultured CLL cells stimulates angiogenesis in the chick embryo chorioallantoic membrane (CAM) and this is inhibited by a blocking anti-VEGF antibody. 3 Furthermore, low cell and high serum VEGF levels correlate with a poor clinical outcome in CLL. FGF-2 expression by leukemic cells is associated with advanced disease and resistance to fluradabine. The source and mechanism of production of serum FGF-2 and VEGF in cancer patient are unclear. They may originate from neoplastic cells, but also from tumor-infiltrating cells and circulating peripheral cells, such as macrophages, T lymphocytes and platelets. Another possible source of angiogenic factors is the extracellular matrix, where they are stored and can be mobilized by proteases secreted by tumor cells.
MC release a variety of factors known to enhance angiogenesis, namely heparin and histamine, a variety of cytokines, such as transforming growth factor-b, tumor necrosis factor-a, interleukin-8, FGF-2 and VEGF 4 implicated in normal as well as tumor-associated angiogenesis. Tryptase released by MC plays an important role in neovascularization. Direct addition of tryptase to microvascular endothelial cells cultured on Matrigel caused a pronounced increase of capillary growth, which was suppressed by specific tryptase inhibitors, and tryptase directly induced endothelial cell proliferation in a dose-dependent fashion. Moreover, tryptase activates latent metalloproteinases and plasminogen activator, which degrade the extracellular matrix, where angiogenic cytokines are stored.
MC are strikingly associated with angiogenesis in tumors, where they are preferentially accumulated in peripheral areas and within the surrounding connective tissue, and rest near or around blood or lymphatic vessels. 4 The results of the present study agree with Correspondence previous findings of a high correlation between microvessel counts and both total metachromatic MC and tryptase-reactive MC in Bcell non-Hodgkin's lymphoma, multiple myeloma and myelodysplastic syndromes. [5] [6] [7] [8] In conclusion, our data indicate that the tryptase contained in the secretory granules of MC may be an effector of MCinduced angiogenesis in B-cell CLL. They also suggest that tryptase antagonization could be employed in the treatment of B-cell CLL. 
Chronic myeloid leukaemia (CML) is a myeloproliferative disease of stem cell origin, characterised by the presence of the Philadelphia (Ph) chromosome and a BCR-ABL fusion gene that is believed to be causal to the disease. CML cells display changes in many intracellular signalling pathways normally activated by growth factor receptors, suggesting a variety of mechanisms by which these cells might acquire reduced dependence on normal growth factor stimulation or decreased responsiveness to inhibitory factors. 1 This is now known to involve the autocrine production of growth factors, specifically IL-3 and G-CSF, by the CD34 + leukaemic cells in chronic phase (CP) CML patients.
2,3 Such a mechanism was initially suggested by studies of the effects of enforced expression of p210 BCR-ABL in immortalised growth factor-dependent cell lines. 4, 5 Autocrine production of IL-3 and GM-CSF was later confirmed in p210 BCR-ABL -transduced murine bone marrow cells both before and after their transplantation into irradiated mice. 6, 7 It was therefore of interest to determine whether autocrine growth factor production by primary CML cells in patients also increases their levels in the periphery, and if so, how these change with disease progression. We now describe the interesting results of an analysis of serum samples from a large series of CML patients that show stage-specific changes in circulating levels of G-CSF but not IL-3.
A total of 177 peripheral blood samples (all collected with informed consent) were analysed. Of these, 135 were from CML patients, 38 were from normal controls, and four were from patients with elevated white blood cell (WBC) counts after surgery unrelated to any malignancy. Of the CML patients, 63 were studied in CP including 26 at diagnosis (CP-Dx), 37 on treatment with hydroxyurea or busulphan (CP-Rx), and 22 before and after 400 mg/day oral imatinib. 56 were in accelerated phase/blast crisis (AP/BC) including four who had been initially studied in CP and nine who were studied before and after 600 mg/day oral imatinib, and 16 who had received an allogeneic transplant (postallo BMT) and were in complete molecular remission. All serum samples were frozen (at À201C) until assessment of cytokine content by sensitive ELISA.
The results of both the IL-3 and G-CSF serum measurements are shown in Figure 1 . Serum IL-3 levels averaged o2 pg/ml in normal controls and similar levels were seen in the sera of 14 'normal' postallo BMT CML patients in molecular remission. Notably, the serum IL-3 levels in CML patients with active disease at any stage were not significantly different. These data indicate that the amounts of IL-3 produced by CD34 + CML cells in vivo is insufficient to alter the levels detectable in the circulation, even in patients with advanced disease.
Normal G-CSF levels were 21.271.6 pg/ml (n ¼ 23) and, in sera from four non-malignant controls with elevated WBCs postsurgery, an expected elevation to 43 times the normal value (787 3 pg/ml, Po0.001) was evident. Normal circulating levels were again seen in the postallo BMT group of 'cured' CML patients. However, in CP-Dx patients, the mean G-CSF level was significantly reduced (420-fold, Po0.001). Moreover, the CP-Rx patients given treatments that lowered their WBC count without a cytogenetic response, had a significantly higher mean serum G-CSF level than the CP-Dx group Received 17 December 2002; accepted 24 February 2003
